药物相关自身免疫性肌炎研究进展  

Research progress on drug-related autoimmune myositis

作　　者：史怡 梁钧昱 林进[1] SHI Yi;LIANG Jun-yu;LIN Jin(Department of Rheumatology&Immunology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院风湿免疫科,杭州310003

出　　处：《中国新药杂志》2024年第18期1889-1896,共8页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(82201971);浙江省自然科学基金资助项目(LQ22H100004)。

摘　　要：自身免疫性炎症性肌病(autoimmune inflammatory myopathy,AIM)是一组具有异质性的自身免疫性疾病,通常是特发性的,常累及骨骼肌及肌外脏器。部分自身免疫性肌炎的发生和发展与药物相关:免疫介导坏死性肌病与他汀类药物密切相关,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)可诱发ICI相关肌炎。此外,特发性炎症性肌病的发生以及眼眶自身免疫性肌炎与新型冠状病毒感染(corona virus disease 2019,COVID-19)疫苗接种相关。即使停止相关药物使用,患者病情仍会继续进展,需要接受免疫抑制治疗。本文旨在从流行病学、发病机制、临床特征、治疗及预后4个方面总结目前他汀类药物、COVID-19疫苗、ICI相关肌炎的研究进展,以提高临床认识,早期诊断早期治疗。Autoimmune inflammatory myopathies(AIM)is a heterogeneous group of autoimmune diseases,often referred to idiopathic,frequently featuring involvement of skeletal muscle and extramuscular organs.The occurrence and development of part of autoimmune myositis are related to drugs:immune-mediated necrotizing myopathy is closely related to statins,and immune checkpoint inhibitors(ICIs)can induce ICI-myositis.Additionally,idiopathic inflammatory myopathy and ocular autoimmune myositis can also be related to COVID-19 vaccination under some circumstance.The disease will still progress even if the regarding medication is discontinued,and immunosuppressive therapy is required.This article aims to summarize the current research progress of myositis associated with statins,COVID-19 vaccine and ICIs from four aspects:epidemiology,pathogenesis,clinical features,treatment and prognosis,so as to improve clinical understanding and early diagnosis and treatment.

关 键 词：自身免疫性肌炎 他汀类药物 COVID-19疫苗 免疫检查点抑制剂 

分 类 号：R979.5[医药卫生—药品]